HRH3 and epilepsy: Pitolisant (PIT), which is the first H3R antagonist to reach the market (Wakix®; Bioprojet Pharma—as an orphan drug for the treatment of narcolepsy [37]), also presented effectiveness in different animal models of epilepsy [25,33,38], which could not be confirmed so far in clinical trials [34] (Table 1).